| Literature DB >> 26443527 |
L Haverkamp1, P C van der Sluis2, M G E M Ausems3, S van der Horst2, P D Siersema4, J P Ruurda2, G J A Offerhaus5, R van Hillegersberg6.
Abstract
BACKGROUND: For patients with an identified germline E-cadherin-1 (CDH1) mutation, prophylactic gastrectomy is the treatment of choice to eliminate the high risk of developing diffuse gastric cancer. Laparoscopic total gastrectomy with jejunal pouch reconstruction is a novel approach that may be especially suitable in these patients.Entities:
Keywords: Cancer; E-cadherin; Gastrectomy; Laparoscopy; Prophylactic
Mesh:
Substances:
Year: 2015 PMID: 26443527 PMCID: PMC4641153 DOI: 10.1007/s11605-015-2963-4
Source DB: PubMed Journal: J Gastrointest Surg ISSN: 1091-255X Impact factor: 3.452
Fig. 1Trocar arrangement during prophylactic laparoscopic total gastrectomy. The camera was inserted through the 10-mm para-umbilical trocar port and two 5-mm trocars were used as laparoscopic working ports. The liver retractor was inserted through the 12-mm right para-rectal trocar port. The harmonic scalpel was inserted through the 12-mm para-umbilical port. The horizontal line represents the incision that is used to take out the stomach
Fig. 2Placement of a supporting suture on both sides of the esophagus followed by transection of the esophagus by means of an Endo-GIA stapler
Fig. 3Removal of the gastric resection specimen through the Endopath DextrusTM access port
Fig. 4Creation of a “J”-shaped jejunal pouch, using a 100-mm linear stapler
Fig. 5Creation of an esophagojejunal anastomosis with jejunal pouch with the use of the Orvil circular stapler
Baseline characteristics
| Laparoscopic prophylactic gastrectomy | |
|---|---|
|
| |
| Agea | 40 (22–61) |
| Gender (male/female) | 3:8 |
| BMIa | 27.8 (19.7–35.2) |
| Comorbidities | |
| Diabetes mellitus | 0 |
| COPD | 0 |
| Cardiovascular | 1 |
| ASA score | |
| 1 | 6 |
| 2 | 4 |
| 3 | 1 |
| Smoking | 6 |
| Alcohol | 5 |
aData presented as median (min–max)
Intraoperative and postoperative outcomes
| Laparoscopic prophylactic gastrectomy | |
|---|---|
|
| |
| Duration of surgery (h)a | 4:26 ± 0:49 |
| Blood loss (ml)a | 219 ± 155 |
| Conversion | 1 |
| Complicated course | 5 |
| Postoperative hospital stay (day)b | 10 (7–23) |
| Intensive care stay (day)b | 0 (0–2) |
| Resected lymph nodes ( | 10 (1–25) |
| R0 resection | 11 |
| Mortality | |
| 30-day mortality | 0 % |
| 60-day mortality | 0 % |
aAverage ± standard deviation
bMedian (min–max)
Fig. 6Swiss roll with signet cell in HE staining (a, b), CAM5.2 staining (c), and E-cadherin immunohistochemistry (d)